Form 4: Alkermes Executive Exercises Options, Sells Shares

Alkermes EVP R&D and Chief Medical Officer, Craig C. Hopkinson, exercised stock options and sold a portion of his ordinary shares on February 2, 2026, under a pre-arranged 10b5-1 trading plan.

Summary

• Craig C. Hopkinson, EVP R&D and Chief Medical Officer of Alkermes plc, engaged in stock transactions on February 2, 2026.
• He exercised 5,000 employee stock options at an exercise price of $19.34 per share, simultaneously acquiring 5,000 ordinary shares.
• Following the option exercise, his beneficial ownership of ordinary shares was 66,740.
• He then sold 5,000 ordinary shares at a weighted average price of $34.2449 per share.
• He also sold an additional 4,000 ordinary shares at a price of $33.54 per share.
• All transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on March 14, 2025.
• Following all reported transactions, his direct beneficial ownership of ordinary shares is 57,740.
• His beneficial ownership of derivative securities (employee stock options) decreased by 5,000 to 26,356 after the exercise.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. It's a routine, pre-planned insider transaction for personal financial management, not indicative of new company performance or strategic changes.

Positives

• The executive's transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and transparent approach to managing personal holdings.
• The sale prices ($34.2449 and $33.54) are significantly higher than the exercise price ($19.34), indicating a profitable transaction for the executive.

Negatives

• An executive selling shares, even under a 10b5-1 plan, can sometimes be perceived negatively by investors, though it is a common practice for liquidity and diversification.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding Alkermes plc's future performance or strategic direction.

Management Comments

• This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025.
• This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025.
• The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.67 to $34.64. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request.
• These options are fully vested in accordance with their terms.

Industry Context

StockSavvy.ai notes that executive stock option exercises and subsequent share sales under Rule 10b5-1 plans are standard practices in the pharmaceutical and biotechnology industries. These transactions typically reflect personal financial planning rather than a direct signal about the company's immediate operational performance or strategic shifts, especially when pre-scheduled.

Comparison to Industry Standards

• This filing details a routine insider transaction, specifically an executive exercising vested stock options and selling shares. Such transactions are common across all industries, including pharmaceuticals, and do not directly compare to specific company projects or financial results of competitors like Pfizer, Johnson & Johnson, or Moderna. The key standard here is compliance with SEC regulations for insider trading, which the 10b5-1 plan addresses.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, pre-planned insider transaction. It does not signal a change in company fundamentals or strategy.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Key Dates

Keywords

Alkermes, ALKS, Form 4, Insider Trading, Stock Options, Executive Compensation, Rule 10b5-1, Share Sale, Beneficial Ownership